In Reply Cross-national comparisons are rare because it is challenging to identify comparable cohorts and data on utilization and costs. Dr Schaefer worries that our study may not be representative. We compared patients dying with cancer using the most comparable cohorts available among nations. We focused on cancer decedents, validating findings from the general cohorts on a more homogeneous cohort, and examining a limited but meaningful set of outcomes available in claims data.
Blankart CR, Emanuel EJ, Bekelman JE, for the International Consortium for End-of-Life Research . Characteristics of Patients Dying With Cancer in Developed Countries—Reply. JAMA. 2016;315(24):2732. doi:10.1001/jama.2016.4042